Kura Oncology
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Kura Oncology and other ETFs, options, and stocks.About KURA
Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias.
KURA Key Statistics
Stock Snapshot
As of today, Kura Oncology(KURA) shares are valued at $9.22. The company's market cap stands at 813.96M, with a P/E ratio of -2.90.
On 2026-03-12, Kura Oncology(KURA) stock moved within a range of $8.85 to $9.47. With shares now at $9.22, the stock is trading +4.2% above its intraday low and -2.6% below the session's peak.
Trading volume for Kura Oncology(KURA) stock has reached 1.49M, versus its average volume of 1.76M.
The stock's 52-week range extends from a low of $5.41 to a high of $12.49.
The stock's 52-week range extends from a low of $5.41 to a high of $12.49.
KURA News
Kura Oncology (KURA) came out with a quarterly loss of $0.92 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to a loss of $0.22...
Reports Q4 revenue $17.34M, consensus $35.45M. As of December 31, 2025, Kura had $667.2M in cash, cash equivalents and short-term investments, compared to $727....
Analyst ratings
92%
of 13 ratingsPeople also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.